Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The endocannabinoid system and neuropathic pain
Rafaël Maldonado, Josep-Eladı́ Baños, David Cabañero
Pain (2015) Vol. 157, Iss. Supplement 1, pp. S23-S32
Open Access | Times Cited: 104

Showing 1-25 of 104 citing articles:

Targeting the endocannabinoid system: future therapeutic strategies
Oier Aizpurua‐Olaizola, Izaskun Elezgarai, Irantzu Rico‐Barrio, et al.
Drug Discovery Today (2016) Vol. 22, Iss. 1, pp. 105-110
Open Access | Times Cited: 185
Exploring Novel Therapeutic Targets in the Common Pathogenic Factors in Migraine and Neuropathic Pain
János Tajti, Délia Szok, Anett Csáti, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 4, pp. 4114-4114
Open Access | Times Cited: 56
The Endocannabinoid System and Physical Exercise
Daniela Matei, Dan Trofin, Daniel Andrei Iordan, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 1989-1989
Open Access | Times Cited: 51
The Cannabinoids Δ8THC, CBD, and HU-308 Act via Distinct Receptors to Reduce Corneal Pain and Inflammation
Dinesh Thapa, Elizabeth A. Cairns, Anna-Maria Szczesniak, et al.
Cannabis and Cannabinoid Research (2018) Vol. 3, Iss. 1, pp. 11-20
Open Access | Times Cited: 87
Neuropathic pain: From actual pharmacological treatments to new therapeutic horizons
Maxime Thouaye, İpek Yalçın
Pharmacology & Therapeutics (2023) Vol. 251, pp. 108546-108546
Open Access | Times Cited: 29
Medical Cannabis for Chronic Nonmalignant Pain Management
Maha Hameed, Sakshi Prasad, Esha Jain, et al.
Current Pain and Headache Reports (2023) Vol. 27, Iss. 4, pp. 57-63
Open Access | Times Cited: 27
Medical Cannabis for Neuropathic Pain
Gemayel Lee, Brittany Grovey, Timothy Furnish, et al.
Current Pain and Headache Reports (2018) Vol. 22, Iss. 1
Closed Access | Times Cited: 80
Cannabinoids therapeutic use: what is our current understanding following the introduction of THC, THC:CBD oromucosal spray and others?
Mauro Maccarrone, Rafaël Maldonado, Miguel Casas, et al.
Expert Review of Clinical Pharmacology (2017) Vol. 10, Iss. 4, pp. 443-455
Closed Access | Times Cited: 74
Rare genetic variants in the endocannabinoid system genes CNR1 and DAGLA are associated with neurological phenotypes in humans
Douglas R. Smith, Christine M. Stanley, Theodore Foss, et al.
PLoS ONE (2017) Vol. 12, Iss. 11, pp. e0187926-e0187926
Open Access | Times Cited: 66
<p>A Review of Scientific Evidence for THC:CBD Oromucosal Spray (Nabiximols) in the Management of Chronic Pain</p>
Michael A. Überall
Journal of Pain Research (2020) Vol. Volume 13, pp. 399-410
Open Access | Times Cited: 65
Topical Treatments and Their Molecular/Cellular Mechanisms in Patients with Peripheral Neuropathic Pain—Narrative Review
Magdalena Kocot-Kępska, Renata Zajączkowska, Joanna Mika, et al.
Pharmaceutics (2021) Vol. 13, Iss. 4, pp. 450-450
Open Access | Times Cited: 45
Efficacy of cannabis-based medications compared to placebo for the treatment of chronic neuropathic pain: a systematic review with meta-analysis
Bradley Sainsbury, Jared Bloxham, M. Pour, et al.
Journal of Dental Anesthesia and Pain Medicine (2021) Vol. 21, Iss. 6, pp. 479-479
Open Access | Times Cited: 44
Peripheral Mechanisms of Neuropathic Pain—The Role of Neuronal and Non-Neuronal Interactions and Their Implications for Topical Treatment of Neuropathic Pain
Magdalena Kocot-Kępska, Renata Zajączkowska, Joanna Mika, et al.
Pharmaceuticals (2021) Vol. 14, Iss. 2, pp. 77-77
Open Access | Times Cited: 42
Central Neuropathic Pain Syndromes: Current and Emerging Pharmacological Strategies
Katharine N. Gurba, Rida Chaudhry, Simon Haroutounian
CNS Drugs (2022) Vol. 36, Iss. 5, pp. 483-516
Closed Access | Times Cited: 29
Clinical outcome data of chronic pain patients treated with cannabis-based oils and dried flower from the UK Medical Cannabis Registry
James Tait, Simon Erridge, Carl Holvey, et al.
Expert Review of Neurotherapeutics (2023) Vol. 23, Iss. 4, pp. 413-423
Open Access | Times Cited: 17
Targeting Peripherally Restricted Cannabinoid Receptor 1, Cannabinoid Receptor 2, and Endocannabinoid-Degrading Enzymes for the Treatment of Neuropathic Pain Including Neuropathic Orofacial Pain
Mohammad Zakir Hossain, Hiroshi Ando, Shumpei Unno, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 4, pp. 1423-1423
Open Access | Times Cited: 47
Translational neuropathic pain research
Nadine Attal, Didier Bouhassira
Pain (2019) Vol. 160, Iss. 1, pp. S23-S28
Closed Access | Times Cited: 45
John J. Bonica Award Lecture: Peripheral neuronal hyperexcitability: the “low-hanging” target for safe therapeutic strategies in neuropathic pain
Srinivasa N. Raja, Matthias Ringkamp, Yun Guan, et al.
Pain (2020) Vol. 161, Iss. Supplement 1, pp. S14-S26
Open Access | Times Cited: 42
Protective role of neuronal and lymphoid cannabinoid CB2 receptors in neuropathic pain
David Cabañero, Angela Ramírez‐López, Eva Drews, et al.
eLife (2020) Vol. 9
Open Access | Times Cited: 40
The endocannabinoidome in neuropsychiatry: Opportunities and potential risks
Gerwyn Morris, Ken Walder, Stefan Kloiber, et al.
Pharmacological Research (2021) Vol. 170, pp. 105729-105729
Closed Access | Times Cited: 33
Cannabis sativa L. Extract Alleviates Neuropathic Pain and Modulates CB1 and CB2 Receptor Expression in Rat
Joanna Bartkowiak-Wieczorek, Agnieszka Bienert, Kamila Czora-Poczwardowska, et al.
Biomolecules (2024) Vol. 14, Iss. 9, pp. 1065-1065
Open Access | Times Cited: 5
The endocannabinoid system as a therapeutic target in neuropathic pain: a review
Jose-Manuel Quintero, Luis E. Díaz, Ismael Galve‐Roperh, et al.
Expert Opinion on Therapeutic Targets (2024) Vol. 28, Iss. 9, pp. 739-755
Closed Access | Times Cited: 5
UK Medical Cannabis Registry: An Analysis of Outcomes of Medical Cannabis Therapy for Hypermobility‐Associated Chronic Pain
Miriam Dickinson, Simon Erridge, John Warner‐Levy, et al.
ACR Open Rheumatology (2025) Vol. 7, Iss. 3
Open Access
Early oral administration of THC:CBD formulations prevent pain-related behaviors without exacerbating paclitaxel-induced changes in weight, locomotion, and anxiety in a rat model of chemotherapy-induced neuropathy
Delia Soriano, Pablo R. Brumovsky, Marcelo J. Villar, et al.
Psychopharmacology (2025)
Closed Access
Antinociceptive effects of HUF-101, a fluorinated cannabidiol derivative
Nicole Rodrigues da Silva, Felipe V. Gomes, Miriam M. Fonseca, et al.
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2017) Vol. 79, pp. 369-377
Closed Access | Times Cited: 44
Page 1 - Next Page

Scroll to top